Loading clinical trials...
Loading clinical trials...
Busulfan, Etoposide, Cytarabine, and Melphalan (BuEAM) as a Conditioning for Autologous Stem Cell Transplantation in Patients With B Cell Lymphoma Except for Diffuse Large B Cell Lymphoma
Conditions
Interventions
Busulfan, etoposide, cytarabine, and melphalan
Locations
5
South Korea
Inje University Busan Paik Hospital, Inje University College of Medicine
Busan, South Korea
Seoul National University Hospital, Seoul National University College of Medicine
Seoul, South Korea
Severance Hospital, Yonsei University College of Medicine
Seoul, South Korea
Asan Medical Center, University of Ulsan College of Medicine
Seoul, South Korea
Ulsan University Hospital, University of Ulsan College of Medicine
Ulsan, South Korea
Start Date
July 1, 2010
Primary Completion Date
December 1, 2014
Last Updated
August 25, 2014
NCT06189391
NCT05006716
NCT06026319
NCT05950165
NCT06876662
NCT05755087
Lead Sponsor
Seoul National University Hospital
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions